Premedication with benzodiazepines for upper gastrointestinal endoscopy: Comparison between oral midazolam and sublingual alprazolam
Vahid Sebghatollahi1, Elham Tabesh1, Ali Gholamrezaei2, Amir Reza Zandi3, Mohammad Minakari1, Ahmad Shavakhi1
1 Department of Internal Medicine, Division of Gastroenterology, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders, University of Leuven, Leuven, Belgium
3 Medical Student's Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
|Date of Submission||31-May-2017|
|Date of Decision||30-Aug-2017|
|Date of Acceptance||10-Sep-2017|
|Date of Web Publication||26-Dec-2017|
Dr. Elham Tabesh
Department of Internal Medicine, Isfahan University of Medical Sciences, Hezar Jarib Street, Isfahan
Source of Support: None, Conflict of Interest: None
Background: Premedication with orally administered benzodiazepines is effective in reducing anxiety and discomfort related to endoscopic procedures. We evaluated the efficacy and safety of oral midazolam in comparison to sublingual alprazolam as premedication for esophagogastroduodenoscopy (EGD). Materials and Methods: Adult candidates for diagnostic EGD received either oral midazolam (7.5 mg in 15 cc apple juice) or sublingual alprazolam (0.5 mg) 30 min before EGD. Procedural anxiety and pain/discomfort were assessed using 11-point numerical rating scales. Patients' overall tolerance (using a four-point Likert scale) and willingness to repeat the EGD, if necessary, were also assessed. Blood pressure, heart rate, and arterial oxygen saturation were monitored from medication to 30 min after the procedure. Results: Patients experienced a similar reduction in procedural anxiety after medication with oral midazolam and sublingual alprazolam; mean (standard deviation [SD] of 1.86 [1.63] and 2.02 [1.99] points, respectively, P = 0.91). Compared to oral midazolam, pain/discomfort scores were lower with sublingual alprazolam; mean (SD) of 4.80 (3.01) versus 3.68 (3.28), P = 0.024. There was no significant difference between the two groups in patients' tolerance, willingness to repeat the procedure, or hemodynamic events. Conclusion: Oral midazolam and sublingual alprazolam are equally effective in reducing EGD-related anxiety; however, EGD-related pain/discomfort is lower with alprazolam. Both benzodiazepines are equally safe and can be used as premedication for patients undergoing diagnostic EGD.
Keywords: Anxiety, benzodiazepines, endoscopy, esophagogastroduodenoscopy, premedication, sedation
|How to cite this article:|
Sebghatollahi V, Tabesh E, Gholamrezaei A, Zandi AR, Minakari M, Shavakhi A. Premedication with benzodiazepines for upper gastrointestinal endoscopy: Comparison between oral midazolam and sublingual alprazolam. J Res Med Sci 2017;22:133
|How to cite this URL:|
Sebghatollahi V, Tabesh E, Gholamrezaei A, Zandi AR, Minakari M, Shavakhi A. Premedication with benzodiazepines for upper gastrointestinal endoscopy: Comparison between oral midazolam and sublingual alprazolam. J Res Med Sci [serial online] 2017 [cited 2020 Jun 1];22:133. Available from: http://www.jmsjournal.net/text.asp?2017/22/1/133/221514
| Introduction|| |
Esophagogastroduodenoscopy (EGD) is a common procedure for investigating various medical conditions. Besides procedural anxiety, EGD can cause pain or discomfort for many patients. Anxiety can increase pain/discomfort during the procedure which, in turn, decreases patient's tolerance., Appropriate sedation can decrease procedural anxiety and discomfort and increase patient's tolerance and satisfaction.,,
Intravenous administration of benzodiazepines (e.g., midazolam) is a popular sedation method in endoscopic procedures., However, intravenous sedation requires close patient monitoring, full equipment, and trained personnel for managing possible serious hemodynamic events., Non-intravenous (oral, sublingual, intranasal) administration of benzodiazepines may be a cost-effective alternative sedation method for EGD. Evidence has shown that such methods can reduce procedural anxiety and discomfort and increase patient's tolerance and satisfaction.,,,,
Although it is shown that oral midazolam is an effective premedication for endoscopic procedures,, it is not widely available and yet has a higher cost comparing to other benzodiazepines. Moreover, there is a concern regarding hemodynamic side effects with its use.,, Among other benzodiazepines, alprazolam has a relatively rapid onset and short duration of action and has been applied effectively for sedation before surgery,, and also for diagnostic EGD. However, only a few head-to-head comparisons between benzodiazepines are conducted so far, most of them in children. Accordingly, we compared the efficacy and safety of oral midazolam and alprazolam in reducing anxiety and pain/discomfort associated with EGD in adult patients.
| Materials and Methods|| |
Participants and study settings
This study was conducted at the endoscopy unit of Alzahra University Hospital (Isfahan, Iran) from September 2016 to February 2017. Elective diagnostic EGD candidates were evaluated according to the following inclusion criteria: age between 18 and 65 years, the first experience of EGD, American Society of Anesthesiology physical status class of I or II, and willingness to participate in the study. Patients with the following characteristics were not included into the study: severe psychiatric, neurologic, cardiac, pulmonary, or other serious diseases interfering with conducting the study or outcome assessment; concomitant treatment with benzodiazepines; current opium use or alcohol consumption; history of allergy to lidocaine or benzodiazepines; history of surgery on upper gastrointestinal tract; and current pregnancy or lactation. Patients who needed therapeutic endoscopic intervention or additional intravenous sedatives during EGD were excluded from the study. The study was approved by the Ethics Committee of the Isfahan University of Medical Sciences (protocol ID 395569) and was registered in the clinicaltrials.gov (NCT03130842). Informed consent was obtained from all patients.
The study was designed as a comparative clinical trial with two parallel arms. Eligible patients were consecutively entered into the study and were alternately allocated into two groups of oral midazolam or sublingual alprazolam. Allocation was performed based on the day of the procedure; all patients in the same day received the same medication. The nursing team was responsible for providing the medications to the patients. The nursing team and the gastroenterologist who performed the procedure were aware of the study arms and the premedication that patients received. Patients were informed (with the consent form or verbally for illiterates) about receiving an active medication that could reduce their anxiety (if any) and increase their tolerance during the endoscopy. They were aware that two non-intravenous medications are going to be compared in this study but were blinded to the name of the medications.
Patients in the oral midazolam group received midazolam hydrochloride (7.5 mg, Tehran Chemie Pharmaceutical Co., Tehran, Iran) mixed with 15 cc apple juice to be taken orally at 30 min before the procedure. Patients in the sublingual alprazolam group received one tablet of the standard oral formulation of alprazolam 0.5 mg (Sobhan Co., Tehran, Iran) to use sublingually at 30 min before the procedure. Lidocaine spray 10% (Sina Darou Co., Tehran, Iran) was applied for local pharyngeal anesthesia before the procedure. Endoscopy was performed for all patients by an experienced gastroenterologist (VS) using the same devices (PENTAX Medical, NJ, USA). For patients with extreme discomfort and lack of tolerance during the procedure, 2 mg midazolam was slowly injected intravenously at the discretion of the endoscopist.
The study primary outcomes included (1) EGD-related anxiety and (2) pain/discomfort. Anxiety was assessed before the drug administration (baseline) and then just before EGD (30 min after medication) using a numerical rating scale, scored from 0 (no anxiety) to 10 (the most anxiety). Pain/discomfort related to EGD was evaluated when patients were fully alert (at the discretion of the nursing team) using a numerical rating scale scored from 0 (no pain/discomfort) to 10 (the most pain/discomfort).
Patient's overall tolerance and satisfaction, willingness to repeat the procedure in future (if necessary), duration of the procedure, and hemodynamic events were considered as the secondary outcomes. Patient's tolerance was evaluated using a four-point Likert scale (poor to excellent tolerance). Satisfaction was assessed using a numerical rating scale scored from 0 (the least satisfaction) to 10 (completely satisfied). Blood pressure, heart rate, and arterial oxygen saturation were recorded at baseline, at the beginning of the EGD, and then at 5 min intervals up to 30 min after starting the procedure (Cardioset LX110, Isfahan Optics Industries Co., Isfahan, Iran). Hypotension episode was defined as systolic blood pressure of <90 mmHg, bradycardia as heart rate of <60 bpm, and desaturation as arterial oxygen saturation of <90%. The nursing team who administered the medication to patients also was responsible to assess the study outcomes.
Sample size was calculated based on the equivalency of the two drugs in reducing EGD-related anxiety with equivalence limit considered as 20%. Sample size was calculated as 72 participants for each of the study groups considering a study power of 80% and type I error of 2.5% (Bonferroni-type adjustment for the two primary outcomes) and a dropout rate of about 10%.
Data were analyzed using IBM ® SPSS ® Statistics for Windows version 24.0 (IBM Corp., Armonk, NY, USA). Continuous variables were checked for normal distribution using one-sample Kolmogorov–Smirnov Test. Data are presented as means ± standard deviation (SD) for continuous variables. Categorical data are presented as number and percentage (%). Independent Samples t-test (for normally distributed data), Mann–Whitney U-test (for non-normally distributed data), and Chi-square or Fisher's exact tests (for categorical data) were applied for comparisons between the two groups. The Wilcoxon test was used to test change in anxiety score before and after medication (since data were not normally distributed). More detailed analyses of the hemodynamic variables are explained in supplementary data [Appendix 1 [Additional file 1]]. P < 0.025 was considered significant for analysis of the two primary outcomes (Bonferroni-type adjustment). No correction was applied for the secondary outcomes (P < 0.05 was considered statistically significant).
| Results|| |
A total of 136 patients were included in the study and were allocated to the study groups [Figure 1]. Two patients in the alprazolam group required intravenous sedation during EGD (between-group comparison, P = 0.241). The study groups were similar regarding demographic data and baseline characteristics [Table 1].
|Table 1: Comparison of demographic data and baseline hemodynamic variables and anxiety score between the two study groups|
Click here to view
Primary and secondary outcomes
According to the Wilcoxon test, anxiety was significantly reduced with midazolam (mean ± SD of reduction = 1.86 ± 1.63, P < 0.001) as well as with alprazolam (mean ± SD of reduction = 2.02 ± 1.99, P < 0.001). Patients in both groups experienced equal reduction in anxiety after using the medication (34.7% vs. 42.2%, P = 0.44) [Table 2]. Pain/discomfort scores were significantly lower with alprazolam compared to the midazolam (4.80 ± 3.01 vs. 3.68 ± 3.28, P = 0.024). There was no significant difference between the two groups in tolerance, satisfaction, willingness to repeat the procedure, and duration of the procedure [Table 2].
|Table 2: Comparison of the primary and secondary outcomes between the two study groups|
Click here to view
Hypotension and bradycardia episodes were rare, transient, and with no significant difference between the two groups [Table 2]. Desaturation was relatively more common compared to other events (11.9%, 16 out of 134). There was no significant difference between the study groups in cumulative hemodynamic events [Table 2]. Hemodynamic changes are presented in [Figure 2] to [Figure 3],[Figure 4]. More details are provided in supplementary data [Appendix 1].
|Figure 2: Systolic blood pressure (±1 standard error of the mean) at baseline and during and after endoscopy. *Significant Group X time interaction and between-group difference, P < 0.05|
Click here to view
|Figure 3: Heart rate (±1 standard error of the mean) at baseline and during and after endoscopy. *Significant between-group difference using Mann–Whitney U-test (P < 0.05)|
Click here to view
|Figure 4: Arterial oxygen saturation (±1 standard error of the mean) at baseline and during and after endoscopy. No significant Group X time interaction or between-group difference (P > 0.05)|
Click here to view
| Discussion|| |
This study is the first head-to-head comparison between two benzodiazepines in adults undergoing EGD and showed that sublingual alprazolam is as efficient as oral midazolam for reducing procedural anxiety as well as increasing patient's tolerance and satisfaction with the procedure. Pain/discomfort was lower with alprazolam compared to midazolam. The two drugs were similar regarding hemodynamic events. Frequency of desaturation episodes with oral midazolam in our study (8.8%) was higher compared to a previous study (4.5%), and patients had relatively more common desaturation episodes with sublingual alprazolam (15.2%). Accordingly, patients must be monitored more closely for possible excessive sedation that can cause respiratory depression.
The variability in the efficacy and difficulty in dose titration of oral administration of benzodiazepines is a disadvantage compared with intravenous use of these drugs. Shavakhi et al. showed that the efficacy of alprazolam can be increased by sublingual (compared to oral) administration. Midazolam can be administered intranasally which has a faster onset of action and higher bioavailability compared to its oral administration. Studies in patients with claustrophobia found less anxiety and more sedation with intranasal midazolam compared to placebo  or oral midazolam. However, another study could not find a benefit for intranasal midazolam over placebo for patients undergoing EGD. Therefore, further studies are needed to investigate the optimal route of administration, dosage, and time interval between drug administration and EGD for premedication with non-intravenous benzodiazepines. Combination with non-pharmacological treatments (e.g., providing patient information materials ,) may increase the efficacy of premedication while has no additional risk and therefore warrants further investigation.
There are some limitations to this study worth mentioning: (1) we could not use a third group with placebo as the control because of ethical concern. Hence, the study design was comparative trial. (2) We applied alternative allocation for assigning patients to the study groups which is not a standard randomization method though the two groups were similar in baseline characteristics. (3) Preparation and administration of the study drugs in the same format (sublingual midazolam tablet) was not possible for us, and therefore, patients and investigators were not blinded to the study arms which might have affected our findings. (4) Although our study sample size was appropriate for the study primary outcomes, since hemodynamic side effects were not common, investigation and comparison of the safety of oral benzodiazepines required larger sample size.
| Conclusion|| |
We found that sublingual alprazolam is as effective and safe as oral midazolam for sedation during EGD. They were similar in reducing procedural anxiety, and patients had similar tolerance and satisfaction with both treatments; however, sublingual alprazolam was accompanied with less pain/discomfort during EGD. Hemodynamic side effects were rare and transient with these benzodiazepines though caution should be taken for desaturation during procedure. We recommend premedication with either sublingual alprazolam or oral midazolam, depending on availability and costs, for patients undergoing diagnostic EGD. Further studies on optimizing the efficacy of premedication by combination with non-pharmacological interventions and also investigating the optimal route of administration, dosage, and time of administration are suggested.
This study was supported by the Isfahan University of Medical Sciences (Grant No. 395569). Authors are thankful to Dr. Samaneh Khanpour Ardestani (University of Alberta, Canada) for editing this report.
Financial support and sponsorship
This study was financially supported by the Isfahan University of Medical Sciences (Grant No. 395569).
Conflicts of interest
There are no conflicts of interest.
| References|| |
Brandt LJ. Patients' attitudes and apprehensions about endoscopy: How to calm troubled waters. Am J Gastroenterol 2001;96:280-4.
Campo R, Brullet E, Montserrat A, Calvet X, Moix J, Rué M, et al.
Identification of factors that influence tolerance of upper gastrointestinal endoscopy. Eur J Gastroenterol Hepatol 1999;11:201-4.
Lee SY, Son HJ, Lee JM, Bae MH, Kim JJ, Paik SW, et al.
Identification of factors that influence conscious sedation in gastrointestinal endoscopy. J Korean Med Sci 2004;19:536-40.
Abraham NS, Fallone CA, Mayrand S, Huang J, Wieczorek P, Barkun AN. Sedation versus no sedation in the performance of diagnostic upper gastrointestinal endoscopy: A Canadian randomized controlled cost-outcome study. Am J Gastroenterol 2004;99:1692-9.
Cohen LB, Delegge MH, Aisenberg J, Brill JV, Inadomi JM, Kochman ML, et al.
AGA Institute review of endoscopic sedation. Gastroenterology 2007;133:675-701.
McQuaid KR, Laine L. A systematic review and meta-analysis of randomized, controlled trials of moderate sedation for routine endoscopic procedures. Gastrointest Endosc 2008;67:910-23.
Arrowsmith JB, Gerstman BB, Fleischer DE, Benjamin SB. Results from the American Society for Gastrointestinal Endoscopy/U.S. Food and Drug Administration collaborative study on complication rates and drug use during gastrointestinal endoscopy. Gastrointest Endosc 1991;37:421-7.
Daneshmend TK, Bell GD, Logan RF. Sedation for upper gastrointestinal endoscopy: Results of a nationwide survey. Gut 1991;32:12-5.
Kuganeswaran E1, Clarkston WK, Cuddy PG, Quiason SG, Pandya PK, Dierenfeldt WT, et al.
double-blind placebo controlled trial of oral midazolam as premedication before flexible sigmoidoscopy. Am J Gastroenterol 1999;94:3215-9.
Mui LM, Teoh AY, Ng EK, Lee YT, Au Yeung AC, Chan YL, et al.
Premedication with orally administered midazolam in adults undergoing diagnostic upper endoscopy: A double-blind placebo-controlled randomized trial. Gastrointest Endosc 2005;61:195-200.
Rafeey M, Ghojazadeh M, Feizo Allah Zadeh H, Majidi H. Use of oral midazolam in pediatric upper gastrointestinal endoscopy. Pediatr Int 2010;52:191-5.
Hedenbro JL, Ekelund M, Aberg T, Lindblom A. Oral sedation for diagnostic upper endoscopy. Endoscopy 1991;23:8-10.
Liacouras CA, Mascarenhas M, Poon C, Wenner WJ. Placebo-controlled trial assessing the use of oral midazolam as a premedication to conscious sedation for pediatric endoscopy. Gastrointest Endosc 1998;47:455-60.
Martinez JL, Sutters KA, Waite S, Davis J, Medina E, Montano N, et al
. A comparison of oral diazepam versus midazolam, administered with intravenous meperidine, as premedication to sedation for pediatric endoscopy. J Pediatr Gastroenterol Nutr 2002;35:51-8.
de Alencar VM, Gonçalves RD, Cruz AA. Oral medication with diazepam or midazolam associated or not with clonidine for oculoplastic office surgery under local anesthesia. Ophthal Plast Reconstr Surg 2010;26:269-72.
De Witte JL, Alegret C, Sessler DI, Cammu G. Preoperative alprazolam reduces anxiety in ambulatory surgery patients: A comparison with oral midazolam. Anesth Analg 2002;95:1601-6.
Jonas JM, Cohon MS. A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: A review of the literature. J Clin Psychiatry 1993;54:25-45.
Shavakhi A, Soleiman S, Gholamrezaei A, Khodadoostan M, Shavakhi S, Tahery A, et al
. Premedication with sublingual or oral alprazolam in adults undergoing diagnostic upper gastrointestinal endoscopy. Endoscopy 2014;46:633-9.
Choy Y. Treatment of acute procedural anxiety in adults. Stein MB, Hermann R, editors. UpToDate. Waltham, MA: UpToDate Inc. Available form: http://www.uptodate.com
[Last accessed on 2017 Oct 01].
Igea F, Casellas JA, González-Huix F, Gómez-Oliva C, Baudet JS, Cacho G, et al
. Sedation for gastrointestinal endoscopy. Endoscopy 2014;46:720-31.
Hollenhorst J, Münte S, Friedrich L, Heine J, Leuwer M, Becker H, et al.
Using intranasal midazolam spray to prevent claustrophobia induced by MR imaging. AJR Am J Roentgenol 2001;176:865-8.
Tschirch FT, Göpfert K, Fröhlich JM, Brunner G, Weishaupt D. Low-dose intranasal versus oral midazolam for routine body MRI of claustrophobic patients. Eur Radiol 2007;17:1403-10.
Kadkhodaee A, Hajiani E, Masjedizadeh AR, Shayesteh AA, Nejad PA, Hashemi SJ, et al
. Evaluation of the efficacy of intra-nasal midazolam for sedation during upper endoscopy: A randomized clinical pilot study. Iran J Gastroenterol Hepatol (GOVARESH) 2013;18:28-31.
van Zuuren FJ, Grypdonck M, Crevits E, Vande Walle C, Defloor T. The effect of an information brochure on patients undergoing gastrointestinal endoscopy: A randomized controlled study. Patient Educ Couns 2006;64:173-82.
Luck A, Pearson S, Maddern G, Hewett P. Effects of video information on precolonoscopy anxiety and knowledge: A randomised trial. Lancet 1999;354:2032-5.
[Figure 1], [Figure 2], [Figure 3], [Figure 4]
[Table 1], [Table 2]